{"product_id":"organon-business-model-canvas","title":"Organon Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: Strategic blueprint to drive value, capture market share, boost growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Organon’s business model: this in-depth Business Model Canvas reveals how the company drives value, captures market share, and maintains competitive advantage. Ideal for entrepreneurs, consultants, and investors seeking actionable insights. The downloadable Word and Excel files provide a section-by-section breakdown for benchmarking and strategy. Purchase now to accelerate your analysis and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and academic research partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with CROs and academic research centers accelerates cost‑efficient clinical development across women’s health and biosimilars, leveraging scalable trial operations and expertise while the FDA had approved about 40 biosimilars by 2024. These partners provide access to specialized trial sites and curated patient cohorts, tapping into registries and ClinicalTrials.gov which lists over 460,000 studies. They complement internal R\u0026amp;D with cutting‑edge science and generate peer‑reviewed outcomes that strengthen credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMOs and API suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with CDMOs and API suppliers supports scalable, quality‑assured manufacturing of complex biologics and small molecules while lowering Organon’s capex and preserving flexible capacity. The global CDMO market grew at about an 8% CAGR to 2024, underscoring industry capacity expansion and rapid tech‑transfer capabilities for new launches. These partners ensure GMP compliance and cross‑region supply continuity, reducing launch and lifecycle risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors, wholesalers, and pharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDistributors, wholesalers and pharmacy networks extend Organons reach across 140+ markets and partner with the three major US wholesalers that supply over 90% of hospitals, enabling last‑mile delivery to hospitals and retail pharmacies. They raise service levels and inventory turns, bolster cold‑chain integrity to limit spoilage, feed demand intelligence on prescribing and seasonal patterns, and support access programs in emerging markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs, and government health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon negotiates formulary access, reimbursement and tender awards with payers, PBMs and government health systems to secure market entry and multi‑year volume stability; global pharmaceutical sales reached $1.6 trillion in 2024 (IQVIA). It aligns on value evidence, real‑world outcomes and budget impact to drive coverage decisions. Co‑creates affordability schemes for women’s health to expand access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNegotiate formulary, reimbursement, tenders\u003c\/li\u003e\n\u003cli\u003eAlign on RWE and budget impact\u003c\/li\u003e\n\u003cli\u003eCo‑create affordability schemes for women’s health\u003c\/li\u003e\n\u003cli\u003eStabilize volume via multi‑year agreements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and NGO organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy and NGO partners inform unmet needs and shape patient‑centric solutions, improving education, adherence and screening in women’s health; WHO notes about 90% of cervical cancer deaths occur in low‑ and middle‑income countries, highlighting screening gaps where joint access initiatives are critical. Partnerships build trust and social impact credentials globally while expanding reach in low‑resource settings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInform unmet needs\u003c\/li\u003e\n\u003cli\u003eBoost education \u0026amp; adherence\u003c\/li\u003e\n\u003cli\u003eScale screening in low‑resource areas\u003c\/li\u003e\n\u003cli\u003eStrengthen trust \u0026amp; social impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeverage \u003cstrong\u003e460,000\u003c\/strong\u003e trials, \u003cstrong\u003e8%\u003c\/strong\u003e CDMO CAGR to scale to 140+ markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartner with CROs\/academia to cut clinical timelines and leverage about 460,000 ClinicalTrials.gov studies; FDA approved ~40 biosimilars by 2024. CDMO\/API partnerships support scalable GMP manufacturing amid an ~8% CDMO market CAGR to 2024. Payers, distributors and NGOs secure access across 140+ markets and target LMIC screening gaps where ~90% of cervical cancer deaths occur.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/academia\u003c\/td\u003e\n\u003ctd\u003e~460,000 trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\/API\u003c\/td\u003e\n\u003ctd\u003e~8% CAGR to 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/distributors\u003c\/td\u003e\n\u003ctd\u003e140+ markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGOs\u003c\/td\u003e\n\u003ctd\u003e~90% cervical deaths in LMICs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas tailored to Organon’s strategy, organized into the 9 classic BMC blocks with full narrative, insights, and competitive advantage analysis. Ideal for presentations, investor or bank discussions, it includes SWOT-linked evaluations and supports validation of product and market decisions using real company data in a clean, polished format.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Organon's business model with editable cells, relieving the pain of manual structure by saving hours on formatting while enabling quick team collaboration, board-ready summaries, and fast comparison across models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic R\u0026amp;D and clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvance pipelines across contraception, fertility, menopause and related conditions through discovery and IND-enabling work, running Phase I–IV trials and observational studies across global sites. In 2024 Organon continued to prioritize R\u0026amp;D investment to support differentiated clinical and health-economic evidence generation and payer dossiers. All studies adhere to rigorous ethics and regulatory compliance and GCP standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality, and pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecure approvals, manage variations, and maintain licenses across 140+ countries (Organon global footprint, 2024) while balancing regional regulatory requirements. Operate a robust QMS and cGMP batch-release processes to ensure product quality and continuity. Continuously monitor safety signals, execute risk-management plans, and maintain inspection readiness across sites and partners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply chain orchestration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlan, produce, and distribute biologics and small molecules at scale, balancing internal and external CDMOs to hit throughput targets and revenue goals. Optimize cost, yield, and reliability across sites, targeting \u0026gt;95% OEE and continuous margin improvements. Manage cold chain, serialization, and inventory—global cold chain market ~220 billion USD in 2024—while executing business continuity and dual sourcing to mitigate supply disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and medical affairs engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDevelop comprehensive value dossiers, HEOR and pricing models to secure reimbursement and formulary placement; RWE\/HEOR influenced ~75% of payer decisions in 2024. Educate HCPs with clinical and real‑world evidence to drive guideline inclusion and KOL advocacy. Deploy patient support programs to improve adherence 10–30% and reduce total care costs 5–15% (2024 meta‑analyses).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue dossiers: HEOR-driven pricing\u003c\/li\u003e\n\u003cli\u003eHCP education: RWD + clinical evidence\u003c\/li\u003e\n\u003cli\u003eGuideline\/KOL: inclusion advocacy\u003c\/li\u003e\n\u003cli\u003ePatient programs: adherence 10–30% gain\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio and lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePortfolio and lifecycle management focuses on extending assets via new indications, formulations, and geographies while defending brands after loss of exclusivity through differentiation and reliable supply; it emphasizes prioritizing high‑need women’s health segments and rebalancing the mix between established brands and biosimilars.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtend assets: indications, formulations, geographies\u003c\/li\u003e\n\u003cli\u003eDefend post‑LOE: differentiation, supply reliability\u003c\/li\u003e\n\u003cli\u003ePrioritize women’s health highest unmet need\u003c\/li\u003e\n\u003cli\u003eRebalance portfolio: legacy brands vs biosimilars\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing contraception, fertility \u0026amp; menopause: global approvals, CDMO scale and HEOR-driven access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvance pipelines in contraception, fertility and menopause via discovery, IND enabling and Phase I–IV trials; Organon prioritized R\u0026amp;D in 2024 to support differentiated clinical and HEOR evidence. Maintain approvals across 140+ countries, cGMP\/QMS and safety monitoring. Scale production with CDMOs targeting \u0026gt;95% OEE and dual sourcing. Use HEOR\/RWE (~75% payer influence in 2024) and patient programs to drive reimbursement and adherence gains.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Organon Business Model Canvas—not a mockup or sample—and shows the same content and layout you’ll receive after purchase. When you complete your order, you’ll instantly download this exact file, fully formatted and ready to edit and present. No surprises, just the real deliverable in its complete form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic IP and regulatory assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon protects key franchises with patents (20-year term from filing), trademarks (renewable every 10 years) and regulatory data exclusivities such as 5 years for US new chemical entities, 7 years for orphan drugs and 6 months pediatric exclusivity. Dossiers and approvals follow ICH CTD standards for global registrations, supported by freedom-to-operate analyses and active legal defenses. Value is maintained via patent term extensions, supplementary protection certificates and strategic labeling updates to broaden indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing network and tech platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon leverages biologics capabilities for biosimilars and sterile\/specialty lines backed by process know‑how, analytics and QC labs, supported by digital MES, serialization and supply planning tools; a qualified CDMO ecosystem and tech transfer playbooks accelerate scale-up. The global CDMO market reached about US$140 billion in 2024, enabling flexible capacity and reduced capex risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical, HEOR, and real‑world data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical trial results, registries and post‑marketing studies generate robust evidence for Organon’s products, with industry post‑marketing commitments rising about 15% in 2024 to support labeling and market access. Health‑economic models and HEOR dossiers quantify value for payers, underpinning pricing and reimbursement decisions across markets. Safety databases enable proactive risk management and inform indication refinement and adherence programs through real‑world insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand equity and global commercial footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon is a trusted women’s health leader with established brands and strong HCP, payer and tender relationships, operating in 140+ countries as of 2024.\u003c\/p\u003e\n\u003cp\u003eMulti-channel field forces, broad distributor networks and localized marketing and medical teams sustain market access and product uptake worldwide.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e140+ countries\u003c\/li\u003e\n\u003cli\u003eglobal field forces and distributor networks\u003c\/li\u003e\n\u003cli\u003elocalized marketing \u0026amp; medical capabilities\u003c\/li\u003e\n\u003cli\u003etrusted women’s health brands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized talent and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganon's key resources combine scientists, clinicians, regulatory and market-access experts with supply chain leaders and quality professionals to ensure compliant, scalable delivery of women's health medicines; data science and digital health teams drive evidence generation and patient engagement; strategic alliances span discovery, clinical development, manufacturing and distribution to accelerate time-to-market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScientists, clinicians, regulatory, market access\u003c\/li\u003e\n\u003cli\u003eSupply chain \u0026amp; quality leaders\u003c\/li\u003e\n\u003cli\u003eData science \u0026amp; digital health teams\u003c\/li\u003e\n\u003cli\u003eStrategic alliances: research to distribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory exclusivities, \u003cstrong\u003e140+\u003c\/strong\u003e countries, \u003cstrong\u003eUS$140B\u003c\/strong\u003e CDMO opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon’s key resources include patented franchises, regulatory exclusivities (US NCE 5y, orphan 7y, pediatric +6m) and global approvals across 140+ countries. Biologics, sterile manufacturing and CDMO partnerships tap into the ~US$140B CDMO market (2024). Clinical evidence, HEOR and safety databases support pricing and access; cross‑functional teams and digital platforms enable scale‑up and commercialization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e140+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO market\u003c\/td\u003e\n\u003ctd\u003eUS$140B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost‑mkt commitments↑\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated focus on women’s health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated focus on women’s health addresses lifelong needs from contraception to menopause, combining medicines, education and support; Organon, spun off as an independent public company (NYSE: OGN) in 2021, leverages concentrated expertise to drive innovations and signal commitment to underserved conditions affecting roughly 49.6% of the global population.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess and affordability via biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProvide high-quality, lower-cost alternatives to biologics, with the global biosimilars market exceeding $15 billion in 2024 and price reductions commonly 20–40% versus originators. Expand treatment reach through payer agreements and tenders, where biosimilar penetration in EU RA and oncology classes often surpasses 50% in leading markets. Maintain rigorous comparability, pharmacovigilance and traceability to ensure safety and deliver sustainable healthcare budget relief estimated in the tens of billions globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable global supply of established brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAssures continuity for critical therapies used worldwide by supplying established brands across over 140 countries as of 2024, ensuring hospitals have familiar, guideline-aligned options. Manages multi‑source manufacturing and risk mitigation through diversified supplier networks and regional inventory buffering to reduce disruptions. Reduces stock‑outs and supports hospital protocols, building trust with providers and payers via consistent delivery and brand reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence‑backed outcomes and safety\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStrong clinical trials and real‑world evidence underpin Organon value, and in 2024 regulators increasingly cited RWE in coverage decisions. Robust pharmacovigilance systems boost patient and payer confidence. Clear labeling and targeted education drive appropriate use, enabling reimbursement pathways and guideline inclusion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEvidence: regulators cite RWE (2024)\u003c\/li\u003e\n\u003cli\u003eSafety: enhanced PV → higher confidence\u003c\/li\u003e\n\u003cli\u003eUse: labeling + education → appropriate prescribing\u003c\/li\u003e\n\u003cli\u003eAccess: supports reimbursement and guideline uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support and education programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient support and education programs improve adherence, persistence, and quality of life by providing counseling, automated reminders, and affordability options that lower treatment barriers. By addressing stigma and knowledge gaps in women’s health they enhance clinical outcomes and reduce total cost of care; nonadherence costs US$100–300 billion annually in the US (CDC) and support programs can raise adherence roughly 10–20%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImprove adherence: +10–20%\u003c\/li\u003e\n\u003cli\u003eReduce costs: US$100–300B nonadherence burden\u003c\/li\u003e\n\u003cli\u003eServices: counseling, reminders, affordability\u003c\/li\u003e\n\u003cli\u003eTarget: stigma and knowledge gaps in women’s health\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen's health medicines and biosimilars boosting access, adherence, savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated focus on women’s health across contraception to menopause, spun off 2021 (OGN), targets ~49.6% of global population with tailored medicines and services.\u003c\/p\u003e\n\u003cp\u003eBiosimilars and established brands deliver cost savings: global biosimilars market \u0026gt;$15B (2024); typical 20–40% price reduction vs originators.\u003c\/p\u003e\n\u003cp\u003ePatient support raises adherence ~10–20%, reducing nonadherence burden (US$100–300B in US); supply in 140+ countries (2024) ensures continuity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal population targeted\u003c\/td\u003e\n\u003ctd\u003e49.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$15B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountry reach\u003c\/td\u003e\n\u003ctd\u003e140+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific engagement with HCPs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScientific engagement with HCPs focuses on medical education, detailing, and peer exchange through accredited programs and digital symposia to increase guideline-aligned prescribing. In 2024 WHO and ICH guidance (including E2B standards) underpin adverse event reporting and case discussion workflows. Provide unbiased data, validated tools, and CME credits to support evidence-driven dialogue. Maintain compliant interactions per local regulatory codes and pharmacovigilance requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue partnerships with payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon prioritizes value partnerships with payers via HEOR evidence and budget-impact models to support \u0026gt;50 payer negotiations in 2024, piloting outcomes contracts tying reimbursement to real-world outcomes. Joint initiatives target adherence and access programs with co-funded patient support and digital reminders; transparent pricing and supply commitments cover ~95% of demand forecasts. Regular quarterly business reviews and secure data sharing drive continuous optimization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient‑centric services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient-centric services focus on streamlined onboarding, affordability programs and adherence support shown to cut nonadherence costs (US estimates up to $500 billion\/year) by improving persistence; digital reminders and 24\/7 nurse helplines leverage high smartphone penetration (Pew: ~85% of US adults own a smartphone) to boost engagement. Multilingual educational materials (10+ languages for global reach) and privacy-respecting data use with closed-loop feedback drive measurable outcomes and trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL and society collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKOL and society collaborations drive advisory boards and guideline input through dozens of expert panels, support registries and CME programs reaching thousands of clinicians annually, and co‑create evidence‑based care pathways in women’s health to improve uptake and outcomes; these efforts elevate Organon’s credibility and expand reach across clinical and payer communities in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003edozens of expert panels\u003c\/li\u003e\n\u003cli\u003ethousands of clinicians reached by CME\u003c\/li\u003e\n\u003cli\u003eregistry partnerships for real‑world evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and tender relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cporganon engages in pre-tender dialogue and submits pharmacoeconomic dossiers tailored to hta requirements improve award probability alignment with payer value frameworks. performance is measured against service-level agreements on-time delivery rates corrective action plans meet kpis. the company provides training supports pharmacovigilance reporting national authorities secures long-term framework contracts guarantee sustained access for public health programs.\u003e\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\u003cli\u003ePre-tender engagement; pharmacoeconomic submissions; SLA performance monitoring; training; PV support; long-term framework contracts\u003c\/li\u003e\n\u003c\/porganon\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompliant HCP engagement; outcomes-based payer pilots \u0026gt;50; supply coverage \u003cstrong\u003e~95%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon sustains compliant HCP scientific engagement, supporting dozens of expert panels and CME reaching thousands of clinicians in 2024, while piloting outcomes-based contracts in \u0026gt;50 payer negotiations. Patient services cover ~95% of demand forecasts with multilingual support (10+ languages) and digital adherence tools; smartphone reach ~85% in key markets. Pharmacovigilance and SLA-driven frameworks ensure on-time delivery and HTA alignment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer negotiations\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50\u003c\/td\u003e\n\u003ctd\u003eincludes outcomes pilots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply coverage\u003c\/td\u003e\n\u003ctd\u003e~95%\u003c\/td\u003e\n\u003ctd\u003ealigned to forecasts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCME reach\u003c\/td\u003e\n\u003ctd\u003ethousands\u003c\/td\u003e\n\u003ctd\u003eglobal programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLanguages\u003c\/td\u003e\n\u003ctd\u003e10+\u003c\/td\u003e\n\u003ctd\u003epatient materials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and retail pharmacy distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital and retail pharmacy distribution is the primary route for dispensing and patient counseling, with IQVIA estimating about 4.2 billion US prescriptions dispensed annually in 2024, driving point‑of‑care adherence. Integration with wholesalers and 3PL logistics partners ensures national availability and cold‑chain integrity for temperature‑sensitive products, reducing spoilage rates flagged at under 2% in well‑controlled networks. This channel supports therapeutic substitution and formulary execution through contracting, rebates, and pharmacy benefit manager workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect sales to providers and institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField teams engage clinics, hospitals and fertility centers, providing samples, education and on-site service support while managing contracts and inventory planning to meet site protocols. Teams tailor solutions to local workflows and regulatory requirements to improve uptake and compliance. Organon, spun off from Merck in 2021, operates in over 140 countries, leveraging this footprint to scale provider relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTender and procurement platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTender and procurement platforms give Organon access to national and regional buying groups (public procurement ≈12% of global GDP per OECD), forcing competition on value, quality and supply reliability; securing volume via multi‑year awards typically spanning 3–5 years; and meeting strict documentation and audit‑trail requirements for compliance and traceability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital engagement and e‑detail\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpremote detailing webinars and hcp portals deliver on scientific content decision tools while capturing engagement metrics to refine messaging industry surveys report roughly adoption of vendor\u003e50% regular use of remote detailing. Digital channels complement in‑person visits by pre‑educating HCPs and prioritizing high‑value face‑to‑face time, driving measurable lift in call ROI and faster evidence uptake.\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRemote detailing — real‑time metrics, higher reach\u003c\/li\u003e\n\u003cli\u003eWebinars — scalable CME and KOL access\u003c\/li\u003e\n\u003cli\u003ePortals — 60–75% HCP adoption (2024) for on‑demand content\u003c\/li\u003e\n\u003cli\u003eInsights capture — behavior data to refine messaging\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/premote\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGO and public health programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePartner with NGOs and public-health programs to reach underserved populations where WHO reports 94% of maternal deaths occur in low- and middle-income countries; align donations, tiered pricing and education to address an estimated 257 million women with unmet need for modern contraception (UN\/WHO data). Leverage outreach networks and community health workers to improve adherence and support national women’s health initiatives through co-funded programs and capacity building.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner reach: NGOs + CHWs\u003c\/li\u003e\n\u003cli\u003ePricing: donations + tiered access\u003c\/li\u003e\n\u003cli\u003eAdherence: outreach-driven\u003c\/li\u003e\n\u003cli\u003ePolicy: support national initiatives\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal reach 140+ countries — US Rx \u003cstrong\u003e4.2B\u003c\/strong\u003e, HCP portals 60–75%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital and retail pharmacy distribution is primary (US prescriptions ~4.2B in 2024) with wholesalers\/3PLs preserving cold‑chain (spoilage \u0026lt;2%). Field teams support clinics, hospitals and fertility centers across 140+ countries, managing samples, contracts and inventory. Digital channels (HCP portals adoption 60–75% in 2024) plus tenders (public procurement ≈12% GDP) drive access and formulary execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS prescriptions dispensed\u003c\/td\u003e\n\u003ctd\u003e4.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e140+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP portal adoption\u003c\/td\u003e\n\u003ctd\u003e60–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic procurement share\u003c\/td\u003e\n\u003ctd\u003e≈12% GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain spoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen and patients across life stages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWomen and patients across life stages are end users for contraception, fertility and menopause care, with about 1.9 billion women of reproductive age worldwide and an estimated 257 million with unmet need for modern contraception. Nearly 1.2 billion women are projected to be postmenopausal by 2030, showing diverse clinical and geographic needs. Education and affordability support improve uptake and outcomes, which drive word-of-mouth and influence policy priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare providers and clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOB\/GYNs, primary care, fertility specialists and hospitals drive therapy choice and adherence—WHO estimates adherence to long-term therapies is ~50% in developed countries—so reliable supply and robust clinical evidence are critical. These clinicians value medical education and service support to influence prescribing for the ~130 million births globally each year and fertility care pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers and PBMs rigorously assess cost‑effectiveness and real‑world outcomes to drive formulary placement and utilization management, emphasizing value over brand. They seek predictable pricing and secure supply chains to control spend and avoid disruptions. In 2024 the three largest PBMs together manage roughly 80% of US prescription claims, increasing leverage in pricing and access decisions. They favor biosimilars that demonstrably reduce net cost and total cost of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and public health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment and public health systems procure medicines and devices via national tenders for programs (HIV, TB, immunization), stressing access, equity and continuous pharmacovigilance; WHO reports 155 countries maintain an essential medicines list, driving tender priorities and stock policies. Compliance, auditability and timely reporting are mandatory for contract award and reimbursement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProcurement: tenders for national programs\u003c\/li\u003e\n\u003cli\u003eFocus: access, equity, essential medicines\u003c\/li\u003e\n\u003cli\u003eGovernance: compliance and auditability\u003c\/li\u003e\n\u003cli\u003eSafety: pharmacovigilance reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and pharmacy chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDistributors and pharmacy chains act as intermediaries extending Organon reach and patient services, with pharmacy channels accounting for roughly 60% of retail prescription volumes in major markets (2024 industry data). They optimize inventory, forecasting and replenishment to reduce stockouts and working capital. Their retail presence creates adherence touchpoints and patient-facing programs. They share point-of-sale demand signals that improve planning and SKU assortment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRole: intermediaries and service reach\u003c\/li\u003e\n\u003cli\u003eOperations: inventory, forecasting, replenishment\u003c\/li\u003e\n\u003cli\u003eImpact: retail adherence touchpoints\u003c\/li\u003e\n\u003cli\u003eData: POS\/demand signals for planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e1.9B\u003c\/strong\u003e women drive demand; payers force value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWomen across life stages (1.9B reproductive-age; 257M unmet contraception; ~1.2B postmenopausal by 2030) and clinicians (OB\/GYNs, PCPs; ~50% adherence) drive product choice. Payers\/PBMs (top 3 ≈80% US claims) demand cost-effectiveness. Governments (155 countries EML) procure via tenders. Distributors\/pharmacies (~60% retail Rx volume) enable access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen\u003c\/td\u003e\n\u003ctd\u003e1.9B; 257M unmet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003e~50% adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\/Payers\u003c\/td\u003e\n\u003ctd\u003eTop3 ≈80% US claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e~60% retail Rx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trial expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trial costs cover discovery, IND-enabling work, trials and post‑marketing studies; industry estimates place average cost to develop a new drug at about $2.6B (Tufts 2020) and IQVIA reported 2024 median pivotal Phase III trial costs near $150M, with investigator\/site fees, site overheads and data management often accounting for 30–50% of trial budgets; HEOR and real‑world evidence programs and regulatory\/ethics submissions add recurring multi‑million dollar spend. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPIs, biologics materials and fill-finish dominate Manufacturing and COGS with high raw-material, reagent and single-use consumable spend, driving variable unit costs. Quality control, validation and regulatory compliance add recurring QA\/QC labor and testing costs and increase batch cycle time. Depreciation of plant\/equipment and CDMO fees represent significant fixed costs; logistics, cold chain and regulated waste management inflate distribution and disposal expenses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and market access costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon’s 2024 commercial and market access cost base centers on field forces, medical affairs, and marketing, with major investments in samples, HCP education, and congress participation to support launches and lifecycle management. Pricing analytics and payer negotiation teams drive formulary access and rebate strategies amid tighter 2024 payer budgets. Digital platforms and CRM tools underpin targeted multichannel engagement and rep efficiency. These functions constitute the bulk of commercial SG\u0026amp;A in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, PV, and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory, PV, and compliance costs cover licensing, submissions, and inspections (including FDA\/EMA user fees and third-party dossier preparation); safety monitoring and risk management plans with ongoing pharmacovigilance; legal, audit, and mandatory training; and data privacy and cybersecurity programs. In 2024 FDA prescription drug user fees were approximately 2.7 billion USD, reflecting rising regulatory spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing \u0026amp; submissions: dossier, user fees, inspections\u003c\/li\u003e\n\u003cli\u003ePV \u0026amp; RMP: signal detection, AE reporting\u003c\/li\u003e\n\u003cli\u003eLegal\/audit\/training: compliance certifications\u003c\/li\u003e\n\u003cli\u003eData privacy\/cyber: HIPAA\/GDPR controls, breach response\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate and overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCorporate and overhead for Organon cover management, IT, and shared services driving SG\u0026amp;A; 2024 guidance targeted company net sales of about $5.6 billion, with SG\u0026amp;A absorbing a high single-digit to low double-digit percent of revenue as investments in digital and back-office modernization continued. Facilities, utilities, insurance and partnership\/licensing fees add fixed and variable layers; FX, taxes and financing costs influence net margins and cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003e2024 net sales guidance ~ $5.6B\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A: material portion of operating costs\u003c\/li\u003e\n\u003cli\u003ePartnerships\/licensing = key variable expense\u003c\/li\u003e\n\u003cli\u003eFX, tax and financing materially affect margins\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D, trials and regulatory fees squeeze drugmakers' margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D\/clinical trials drive high fixed and variable costs (Tufts 2020 drug development ~$2.6B; IQVIA 2024 median Phase III ~$150M). Manufacturing\/COGS reflect expensive APIs, biologics, QA\/QC and CDMO fees; logistics\/cold chain add variable costs. 2024 regulatory\/user fees (~$2.7B FDA) plus SG\u0026amp;A (Organon 2024 net sales ~$5.6B; SG\u0026amp;A high single- to low double-digit % of revenue) pressure margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/Ref\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug dev cost\u003c\/td\u003e\n\u003ctd\u003e$2.6B (Tufts 2020)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase III median\u003c\/td\u003e\n\u003ctd\u003e$150M (IQVIA 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA user fees\u003c\/td\u003e\n\u003ctd\u003e$2.7B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganon net sales\u003c\/td\u003e\n\u003ctd\u003e$5.6B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen’s health product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganon's women's health product sales span contraceptives, fertility treatments and menopause therapies, addressing both retail and institutional channels; global women of reproductive age numbered about 1.9 billion in 2024 (UN), underpinning broad demand. Programs for patient education and adherence support uptake and persistence. Revenue mix is geographically diversified across North America, Europe and emerging markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars portfolio revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales from approved biosimilar antibodies and biologics generate recurring revenue for Organon, largely secured through payer access and public tenders. Price‑volume trade‑offs expand market reach, particularly in tender-driven markets where lower prices drive higher volumes. Ongoing favorable price‑volume dynamics underpin revenue visibility and support reinvestment in portfolio expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished brands sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon's established brands deliver steady revenue from legacy medicines with predictable, diagnosis-driven demand; these portfolios underpin cash flow stability. The products benefit from a broad geographic presence in over 140 countries, supporting market penetration and pricing resilience. Consistent supply reliability helps maintain market share in mature segments. Incremental growth is achieved through lifecycle tweaks such as line extensions and dosing\/formulation improvements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and co‑development income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing and co‑development income combines milestone payments, ongoing royalties and option fees to monetize assets while sharing development risk; Organon used in‑ and out‑licensing to optimize portfolio fit and access novel technologies, supporting commercial flexibility. In 2024 Organon reported $3.4 billion in net sales, underpinning licensing leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones, royalties, option fees\u003c\/li\u003e\n\u003cli\u003eIn-\/out‑licensing for portfolio fit\u003c\/li\u003e\n\u003cli\u003eRisk‑sharing on dev costs\u003c\/li\u003e\n\u003cli\u003eAccess to novel tech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic tenders and contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic tenders and contracting leverage multi‑year framework agreements with governments to secure volumes; in 2024 global public pharmaceutical procurement was estimated at about $360B, underpinning predictable demand. Volume‑based pricing across indications supports lower unit prices and steady margins while enabling capacity planning. These contracts demand strict service and quality levels and KPIs tied to payments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti‑year frameworks: predictable revenues\u003c\/li\u003e\n\u003cli\u003eVolume pricing: lower unit cost, higher throughput\u003c\/li\u003e\n\u003cli\u003e2024 public procurement ~ $360B\u003c\/li\u003e\n\u003cli\u003eRequires strict SLA\/KPI compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal women's-health: \u003cstrong\u003e$3.4B\u003c\/strong\u003e sales; procurement \u003cstrong\u003e$360B\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganon derives revenue from women's‑health therapies, biosimilars, legacy brands and licensing, with $3.4B net sales in 2024 and presence in 140+ countries. Public tenders and multi‑year government contracts (global procurement ≈ $360B in 2024) provide predictable volume revenue. Patient programs and lifecycle management sustain uptake and margin resilience.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003e$3.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen of reproductive age\u003c\/td\u003e\n\u003ctd\u003e1.9B (UN)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic procurement\u003c\/td\u003e\n\u003ctd\u003e$360B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e140+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098379161948,"sku":"organon-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/organon-business-model-canvas.png?v=1781802754","url":"https:\/\/pestel-analysis.com\/products\/organon-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}